Opko Health子公司Modex Therapeutics已正式启动MDX2301的临床试验,该药物旨在用于新冠病毒的预防。此次试验标志着公司在抗病毒治疗领域迈出重要一步。
Opko Health子公司Modex Therapeutics已正式启动MDX2301的临床试验,该药物旨在用于新冠病毒的预防。此次试验标志着公司在抗病毒治疗领域迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.